Anzeige
Mehr »
Login
Samstag, 18.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Spezial Report: NASDAQ-FinTech mit 3.000% Wachstum und 500% Kurs-Chance!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

GlobeNewswire (Europe)-Archiv vom 25.06.2023

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
25.06.23Novo Nordisk A/S: New data show once-weekly insulin icodec met additional endpoints in adults with type 2 diabetes in phase 3a trials1.007After achieving primary endpoint by demonstrating superiority and non-inferiority in HbA1C reduction from baseline at week 52, investigative insulin icodec helped patients achieve significantly more...
► Artikel lesen
25.06.23VEON Ltd.: VEON publishes audited financial statements for year ended 31 December 2022392VEON publishes audited financial statements for year ended 31 December 2022 Amsterdam, 25 June 2023 - VEON Ltd. (NASDAQ: VEON, Euronext Amsterdam: VEON), a global digital operator that provides...
► Artikel lesen
25.06.23Fabrice Brégier is appointed Chairman of SCOR's Board of Directors571Press ReleaseJune 25, 2023 - N° 14 Fabrice Brégier is appointed Chairmanof SCOR's Board of Directors SCOR's Board of Directors, which met on June 25, 2023, has unanimously decided to appoint...
► Artikel lesen
25.06.23Sanofi: ALTUVIIIO late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing759ALTUVIIIOTM late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing XTEND-Kids data confirm the efficacy and safety...
► Artikel lesen
25.06.23MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa569MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa First placebo-controlled randomized trial in HS to report...
► Artikel lesen